Abstract:Objective To investigate the effect of once yearly zoledronic acid of 5 mg on postmenopausal women with osteoporosis of different causes. Methods From October 2009 to December 2009,a total of 89 postmenopausal women with osteoporosis were enrolled and assigned into 2 groups.There were 45 cases of primary postmenopausal osteoporosis,including 27 cases of fresh fracture,in group A.They were aged from 47 to 83 years,with an average of 63.7 years.There were 44 cases of secondary postmenopausal osteoporosis,including 28 cases of fresh fracture,in group B.All patients were given a.single 30-minute intravenous injection of zoledronic acid (5 mg),supplemented by 1,25-dihydroxyvitamin D of 0.25 μg and calcium of 600 mg with VitD125 IU daily.At pre-intervention and 12 months after intervention respectively,bone mineral density (BMD) was measured by dual-X-ray absorptiometry (DXA) at the lumbar spine and hip,and a balance test(Sunlight Tetrax- Ⅱ) was performed to evaluate the risk of falling.Intervention compliance of the patients and adverse events related to zoledronic acid infusion were observed. Results All cases of fresh fracture healed well at 3-month follow-up.At 12 months,43 subjects in group A and 42 subjects in group B completed the follow-up.In group A,BMD increased by 5.8％ at the lumbar spine,by 2.9％ at the femoral neck,by 5.2％ at the Words area,by 5.3％ at the greater trochanter and by 3.9％ at the total hip while the risk of falling decreased by 26.1％; in group B,BMD increased by by 3.4％ at the lumbar spine,by 2.1％ at the femoral neck,by 3.2％ at the Words area,by 3.0％ at the greater trochanter and by 2.5％ at the total hip while the risk of falling decreased by 21.8％.The differences between pre-intervention and post-intervention were significant in both groups ( P ＜ 0.05).No intolerable adverse events occurred in both groups except that one new fracture happened in each group but responded to conservative treatment.Conclusion A once-yearly infusion of zoledronic acid of 5 mg is a convenient and effective therapy for treatment of osteoporosis in postmenopausal women.

Effect of zoledronic acid on blood lipid and bone mineral density in postmenopausal females

Effect of 5 Mg Zoledronic Acid on Bone Mineral Density in Women with Postmenopausal Osteoporosis

The effects of Alendronate on bone mineral density in RA patients with osteoporosis or osteopenia

5 Mg Zoledronic Acid for Treatment of Postmenopausal Women with Osteoporosis and Osteoporotic Fracture

Observation of the efficacy and safety of zoledronic and in postmenopausal osteoporosis

The effect of Zoledronic acid on pain and balance in women with postmenopausal osteoporosis

Effect of Risedronate Sodium on Blood Lipid and Bone Mineral Density

Zoledronic Acid Increases Bone Mineral Density and Improves Health-Related Quality of Life over Two Years of Treatment in Chinese Women with Postmenopausal Osteoporosis.

Use of zoledronic acid in antiosteoporosis treatment is associated with a decreased blood lipid level in postmenopausal women with osteoporosis: A cohort study in China

Efficacy and safety of zoledronic acid in the treatment of osteoporosis: A meta-analysis of randomized controlled trials

Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures

Study of Ibandronate and Alendronate Treatment for Postmenopausal Osteoporosis

Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials

[Phase III Clinical Study of Zoledronic Acid in the Treatment of Pain Induced by Bone Metastasis from Solid Tumor or Multiple Myeloma].

The Effects of Health Education and Comprehensive Lifestyle Modification on Postmenopausal Osteoporosis Women Treatment with Alendronate Sodium

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up

Effects of tibolone combined with zoledronic acid on bone density, bone metabolism, and pain in postmenopausal patients with osteoporosis

Effect of alendronate on bone turnover biomarkers in postmenopausal osteoporosis

Effects of Risedronate on Women with Postmenopausal Osteoporosis

Effect of zoledronic acid on osteoprotegerin and tumor necrosis factor alpha mRNA expression in rats

The Related Variety Analysis of Bone Mineral Density and Blood Lipid in Postmenopausal Osteoporosis Patients with Risedronate Treatment